Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Earnings Results, Beats Expectations By $8.47 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its earnings results on Thursday. The company reported $8.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $8.47, Zacks reports. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%.

Zealand Pharma A/S Stock Up 1.7%

ZLDPF stock traded up $0.88 during trading on Thursday, reaching $52.68. The stock had a trading volume of 180 shares, compared to its average volume of 2,874. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $45.56 and a 200 day moving average price of $49.57. The company has a market capitalization of $3.77 billion, a P/E ratio of 3.91 and a beta of 0.88. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.